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Abstract
A case of a thymic neuroendocrine tumor and the interpretation problems in a post-surgical
Somatostatin Receptor Scintigraphy are presented. In a 53-year-old man with superior vena cava
obstruction syndrome an atypical carcinoid of the thymus (neuroendocrine carcinoma of intermediate
grade 2), was found at surgery.
During his first year of follow-up a Somatostatin Receptor Scintigraphy was recommended. An area
of abnormal concentration of the radiopharmaceutical was revealed in the mediastinum at this time.
A thorough understanding of the mechanisms of the radiopharmaceutical uptake and of the various
clinical settings in which uptake can occur are essential for a proper evaluation of the scintigraphic
findings and result in the optimal use of this valuable modality.
The literature review provides an overview of this rare type of tumor and insight into the clinical
significance of Somatostatin Receptor Scintigraphy.
Introduction
Primary neuroendocrine tumors of the thymus, previ-
ously known as thymic carcinoids, are unusual tumors
that account for less than 5% of all anterior mediastinal
neoplasms. They affect patients over a wide age range,
with the median age being 43 years. Men are more fre-
quently affected than women, with a male to female ratio
of 3:1 [1].
Clinically, these tumors manifest in one of four ways: 1)
as an incidental finding on routine chest radiography, 2)
with symptoms of thoracic structure displacement or
compression, 3) with symptoms related to an associated
endocrinopathy or 4) with symptoms and signs relating to
a distant metastasis, most commonly in the liver, lung,
pancreas, pleura or bone. At least 20% of affected patients
have metastatic disease at presentation, with the fre-
quency of extra-thoracic metastasis being 20% – 30 %
[2,3]. Approximately one-half of thymic neuroendocrine
tumors (TNET) are functionally active and manifest with
clinical hormone-excess syndromes, such as Cushing syn-
drome and are part of the autosomal dominant syndrome
of multiple endocrine neoplasia (MEN) [4]. Type I (MEN)
syndrome is characterized by hyperparathyroidism, islet
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cell tumors of the pancreas, and pituitary adenomas. Car-
cinoids, adrenal adenomas or carcinomas, lipomas and
follicular thyroid adenomas are less frequently associated
neoplasms. The majority of patients with TNET and type I
MEN syndrome are male. Additional associated condi-
tions found in patients with TNET include type 2 MEN
syndrome, inappropriate secretion of antidiuretic hor-
mone, polymyositis, finger clubbing, polyarthropathy,
and myocarditis.
Thoracic CT and MRI and nuclear medicine imaging,
including Somatostatin Receptor Scintigraphy (SRS),
meta-iodobenzylguanidine (MIBG) scintigraphy with I-
123 or I-131 and bone scan, are useful studies in the eval-
uation of these patients [5]. Radio labeled somatostatin
receptor analogues can detect biochemical lesions. This
constitutes an advanced option of "functional" imaging.
The success of imaging a certain lesion depends on the
somatostatin receptor subtypes (SSRT) that are expressed
by the tumor. In-111-DTPA-D-Phe 1-pentetreotide (pen-
tetreotide) has shown highest affinity for SSRT2, SSRT3
and SSRT5. Its total sensitivity in detecting neuroendo-
crine tumors is reported to be 71% – 100% depending on
the histological type of the tumor. MIBG scan sensitivity
has been reported to be 16% – 96% in these tumors [6].
Few reports of cross-sectional imaging features of TNET
have been published; these lesions have been described as
anterior mediastinal masses indistinguishable from thy-
momas at CT. Invasion of focal structures and calcifica-
tion within the tumor have both been reported.
However, pentetreotide has also been shown to concen-
trate in primary and metastatic thymic tumors, including
thymoma, thymic carcinoma, and TNET [7-9] where sub-
type SSRT2 is present in high density.
SRS also may have a role in the follow-up of these patients
[9]. Another potential application of the pre-surgical SRS
is its use as a guide for octreotide therapy [10] and for
radionuclide therapy with radio labeled analogues under
specific conditions and criteria. Systemic injection of
111In-Pentetreotide has yielded tumor growth inhibition
in animal models and in patients with somatostatin
receptor positive tumors, this therefore could be a clinical
application in this kind of tumor [11-13].
Case presentation
A 53-year-old man noticed some swelling of his face. A
chest x-ray showed a large mass projecting over the right
lung field (fig 1). A CT scan of the chest showed an enor-
mous anterior mediastinal mass contiguous with the pos-
terior aspect of the sternum and the right ribs, occluding
the superior vena cava and compressing the heart (fig 2).
Blood tests were normal, tumor markers and Acetyl
Choline Receptor Antibodies were negative. The patient
underwent bronchoscopy and the biopsy showed the fea-
tures of a carcinoid tumor.
He underwent excision of the tumor, which required
resection of the superior vena cava and insertion of a graft,
resection of the right phrenic nerve and plication of the
diaphragm.
The chest x-ray, showing a large mass projecting over the  right lung field Figure 1
The chest x-ray, showing a large mass projecting over the 
right lung field.
A pre-surgical CT scan of the chest showing the tumour Figure 2
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The finding at surgery was an enormous spherical tumor
with an extremely vascular capsule due to the venous
collaterals. The tumor was 20 cm from pole to pole and 15
cm in diameter. On the left it bulged into the left pleural
space, displacing the phrenic nerve laterally. Superiorly it
obliterated the left innominate vein and extend into the
strap muscles. There was an enlarged lymph node. On the
right it had obliterated the confluence of the innominate
veins and the first centimeter or so of the superior vena
cava. It enclosed the phrenic nerve over its complete
length and was adherent to the medial aspects of the
upper and middle lobes of the right lung. There was some
thickening of the visceral pleura in this area and there
appeared to be some superficial infiltration. Posteriorly it
was adherent to the pericardium and there was some
thickening of the ascending aorta, consistent with long-
standing pressure effects. There was a small bloody peri-
cardial effusion and a rather large right pleural effusion.
There was no evidence of any pleural deposits or intraperi-
cardial deposits.
The histology of the resection specimen showed a tumor
weighing 2.1 kg. The tumor appeared encapsulated with
an irregular surface. The tumor invaded the surrounding
fat and pleura. There was infiltration into the underlying
lung tissue lymphatics. There was some residual thymic
tissue within the surrounding fat. Metastatic deposits were
found in the right hilar lymph node and the node
removed from the left cervical horn of the thymus. The
tumor was classified as an atypical carcinoid of the thy-
mus (neuroendocrine carcinoma of intermediate grade
2).
One month later he underwent a CT scan of the chest.
There were findings consistent with a recent sternotomy
and a graft of the superior vena cava. There was a fluid
filled cyst at the base of the right lung and areas of atel-
ectasis and pleural thickening were noted in both lungs.
An I-123 MIBG scan was performed with negative results
for detection of any residual or recurrent pathology.
He was treated with postoperative radiotherapy and
chemotherapy.
One year later, a follow-up CT scan of the chest was
obtained with no findings of recurrence or abnormal
lymph nodes in the mediastinum. Linear atelectasis was
detected in the lower lobes of both lungs and elevation of
the right hemi diaphragm was noted. In addition a bone
scan was performed with a positive finding at the poste-
rior arch of the 8th right rib. The patient was advised to
have a SRS, for a more accurate evaluation of his status, as
it was considered that "functional" imaging performed by
Nuclear Medicine examinations, might detect pathologi-
cal processes earlier than "structural" images, such as CT.
Spot images of head-neck, thorax, abdomen and lumbar
region were obtained 3 hr after injection of 5 mCi In-111-
DTPA-D-Phe 1-pentetreotide. The scan was carried out on
a Sopha single headed tomographic gamma camera cou-
pled to a dedicated NXT computer system. Spot images of
the areas of interest were obtained with a high-energy all-
purpose collimator using 20% windows centered at 171
and 245 keV.
The SRS was reported as showing an area of abnormally
increased concentration of the radiopharmaceutical at the
anatomical area of the mediastinum due to either a mass
remnant or a recurrence of the disease or an inflammatory
process (fig. 3). The bone scan finding did not take up the
radiopharmaceutical. A repeat bone scan after a further 9
months was negative.
Thus, the main questions that we had to answer were: is
there a mass remnant, or a recurrence of the disease? and,
can we exclude a metastatic lesion at the site of the finding
on the bone scan?
Discussion
Although there was no pre-operative SRS, requesting a
post-operative SRS for this patient was justified because of
the histological type of his tumor, the extensive lesions
and the extended and complicated surgical management.
Additionally, it is possible that during surgical maneuvers
some cells were transported and implanted in other
organs, so that post-surgical metastasis had occurred.
Another serious reason for referring such a patient for a
SRS is the finding on the bone scan [14]. Regional lymph
node and distant metastases, including osteoblastic bone
metastases, have been reported in up to 73% of cases and
can occur late. An accidental injury could also be detected
by the bone scan and for a period of 1 year. In the SRS, no
lesion was found compatible with the finding in the bone
scan. This, together with the fact that the bone scan lesion
was solitary, reduces the probability of a metastatic bone
lesion, though the possibility of variation of expression of
SSRTs between metastases and primary tumor remains.
This explains, in part, why the MRI scan is reported to be
a more sensitive method than SRS [5].
The patient underwent a post-surgical 123I MIBG scan that
was negative. The 123I MIBG scan was also performed in
order to detect neuroendocrine tissues, but its sensitivity
is unknown in this tumor. We note that SRS detects pri-
mary and metastatic thymic tumors, including TNET
[7,8,14].International Seminars in Surgical Oncology 2005, 2:7 http://www.issoonline.com/content/2/1/7
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As to the interpretation we gave to the SRS, this could not
be more precise in answering whether there is a mass
remnant or a recurrence of the disease, for the following
reasons:
1. There wasn't a pre-surgical SRS for comparison. So it
was not known whether or not the primary mass could be
imaged with pentetreotide. A negative scan may result
when the SSRTs of the tumor are different from those
detected by the radiopharmaceutical.
2. There have been extended and complicated surgical
maneuvers that may have cause anatomical changes.
3. An inflammatory process may exist in the same area
which could also cause accumulation of the
radiopharmaceutical.
This inflammatory component may be due to post radio-
therapy fibrosis or to co-existing inflammatory reaction in
the atelectasis of the lungs, because of the alveolar wall
thickening and fibrosis.
The atelectasis, may have been caused by the surgical
maneuvers but it is known that linear or disc-like atelecta-
sis is common in the inferior lung lobes secondary to
pleural, pericardial or mediastinal lesions, as was present
in our patient.
It has also been recorded that if an atelectatic lesion has
not resolved after three months, it will not return to nor-
mal tissue and constitutes a favourable site for mild infec-
tions (bronchectasis and pulmonary fibrosis). In these
cases total blood count and ESR remain normal.
Pentetreotide is accumulated in surgical trauma because
of the healing process in which macrophages are
recruited. This fact makes a SRS unable to distinguish the
disease from the healing process. This applies for two
months after the surgery.
In the case of our patient, the SRS was performed one year
after the surgery, so this possibility should be excluded,
although the radiotherapy, which our patient had under-
gone, may have prolonged the healing period.
Two years after the SRS, the patient is free of disease
according to his clinical condition, biochemical data and
imaging modalities, including a MRI scan. A second SRS
that could clarify our finding was not performed since the
MRI scan was negative, and a further study of our finding
was not possible. Thus, the SRS finding has to be inter-
SRS with In-111-DTPA-D-Phe 1-pentetreotide showed an area of abnormally increased concentration of the radiopharmaceu- tical at the anatomical area of the mediastinum Figure 3
SRS with In-111-DTPA-D-Phe 1-pentetreotide showed an area of abnormally increased concentration of the radiopharmaceu-
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preted, based on the above follow up data, as a radiophar-
maceutical accumulation at the site of an inflammatory
process and not as a mass remnant or a recurrence of the
disease.
To our best knowledge, 28 cases of TNET in which SRS
was performed have been reported to date in the literature
(table 1) [5,7-10,15-18], and only one study in abstract
form has reported a patient with TNET with MEN 1 having
a "false" negative SRS [17]. Tiffet et al. [19] in a study of
12 neuroendocrine tumors arising in the thymus, found
that none of the 12 tumors stained positively for somato-
statin receptors, while Boix et al. in a case of a 33 year-old-
woman with MEN 1 described positive somatostatin
receptor staining by immunohistochemistry [20]. From
the first study, it would seem that SRS is not advisable for
post-operative follow up, while from the second, a post-
operative SRS could be performed even if pre-operative
SRS was not done.
Conclusion
Since CT and MRI are more accurate than SRS in the detec-
tion of TNET, the main role of pre-operative SRS is in the
planning of follow up and possible therapeutic
approaches for these patients. The post-operative SRS
should be performed at the right time, so that the healing
process is over and a possible remnant or recurrence can
be detected. All the radiopharmaceutical accumulation
mechanisms have to be taken into account in order to pro-
ceed to a valid differential diagnosis and give precise
information to the clinician.
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